Executives from Insilico Medicine will participate in several major international events in July, highlighting the company's progress in artificial intelligence-driven drug discovery and development.
Dr. Alex Aliper, Co-founder and President of Insilico Medicine, will attend the AI for Good Global Summit 2026 in Geneva, Switzerland on July 7. He is scheduled to join a panel discussion titled "Expanding healthcare access through AI-enabled science" and deliver a keynote speech on "Generative AI for Drug Discovery and Pharmaceutical R&D" at a workshop focused on innovation and standards in pharmaceutical manufacturing. The summit is organized by the International Telecommunication Union with support from United Nations agencies, aiming to address global healthcare inequality, promote sustainable development goals, and shape frameworks for AI governance.
On July 8 in Beijing, Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, will speak at the CITICS Global Consumer and Healthcare Forum 2026. His keynote presentation is titled "From Technical Breakthrough to Clinical Validation: The Second Half of AI Drug Discovery." According to event information, Insilico Medicine has developed over 40 projects using its Pharma.AI platform since 2021; it has nominated 31 development candidates with more than ten receiving Investigational New Drug approvals. A notable program is Rentosertib (ISM001-055), an AI-designed TNIK inhibitor for idiopathic pulmonary fibrosis that recently achieved positive Phase IIa clinical trial results.
The CITICS forum gathers corporate executives, industry experts, policymakers, and investors to discuss shifts in China's consumer market as well as transformations within the healthcare sector driven by innovative drugs and artificial intelligence technologies.
From July 8 to 10 in Hong Kong, Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will participate in LEAP EAST—a major technology exhibition supported by organizations including the Innovation, Technology and Industry Bureau of Hong Kong SAR Government. Zhavoronkov's presentations will cover breakthroughs related to quantum technology-powered research alongside advancements in clinical development using artificial intelligence. LEAP EAST convenes more than 300 exhibitors from around the world focusing on generative AI applications across biomedical technology and smart manufacturing sectors, among others.
These events collectively provide platforms for industry leaders like Insilico Medicine to share insights into how artificial intelligence can advance drug discovery processes while fostering cross-border collaboration toward sustainable solutions.
